ENTRY       D11827                      Drug
NAME        Retifanlimab (USAN);
            Retifanlimab-dlwr;
            Zynyz (TN)
PRODUCT     ZYNYZ (Incyte Corporation)
FORMULA     C6456H9934N1702O2032S46
EXACT_MASS  145289.3476
MOL_WEIGHT  145379.1294
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYSFT SYWMNWVRQA PGQGLEWIGV IHPSDSETWL
            DQKFKDRVTI TVDKSTSTAY MELSSLRSED TAVYYCAREH YGTSPFAYWG QGTLVTVSSA
            STKGPSVFPL APCSRSTSES TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKGLPSS IEKTISKAKG QPREPQVYTL PPSQEEMTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSRLT VDKSRWQEGN
            VFSCSVMHEA LHNHYTQKSL SLSLG
            (Light chain)
            EIVLTQSPAT LSLSPGERAT LSCRASESVD NYGMSFMNWF QQKPGQPPKL LIHAASNQGS
            GVPSRFSGSG SGTDFTLTIS SLEPEDFAVY FCQQSKEVPY TFGGGTKVEI KRTVAAPSVF
            IFPPSDEQLK SGTASVVCLL NNFYPREAKV QWKVDNALQS GNSQESVTEQ DSKDSTYSLS
            STLTLSKADY EKHKVYACEV THQGLSSPVT KSFNRGEC
            (Disulfide bridge: H22-H96, H133-L218, H146-H202, H225-H'225, H228-H'228, H260-H320, H366-H424, H'22-H'96, H'133-L'218, H'146-H'202, H'260-H'320, H'366-H'424, L23-L92, L138-L198, L'23-L'92, L'138-L'198)
  TYPE      Peptide
CLASS       Antineoplastic
             DG02938  Immune checkpoint inhibitor
REMARK      ATC code: L01FF10
            Product: D11827<US>
EFFICACY    Antineoplastic, Immune checkpoint inhibitor, Anti-PD-1 antibody
  DISEASE   Merkel cell carcinoma [DS:H01555]
  TYPE      Monoclonal antibody
TARGET      PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
  PATHWAY   hsa04514(5133)  Cell adhesion molecules
            hsa04660(5133)  T cell receptor signaling pathway
            hsa05235(5133)  PD-L1 expression and PD-1 checkpoint pathway in cancer
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
                 L01FF10 Retifanlimab
                  D11827  Retifanlimab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Retifanlimab
                D11827  Retifanlimab (USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11827  Retifanlimab
            Drug classes [BR:br08332]
             Antineoplastic
              DG02938  Immune checkpoint inhibitor
               D11827  Retifanlimab
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Immune checkpoints
                PDCD1 (PD1, CD279)
                 D11827  Retifanlimab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11827
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11827
DBLINKS     PubChem: 405226692
///
